Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment
ConclusionsThe MTGs-based signature represents a novel approach with promising potential for predicting BCR in PCa patients.
Source: European Journal of Medical Research - Category: Research Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Immunotherapy | Prostate Cancer | Research | Study